Novel inhibitors of the early steps of the HIV-1 life cycle

Bibliography

• COCCHI F, DE VICO AL, GARZINO-DEMO A, ARYA RC, GALLO RC, LUSSO P: Identification of RANTES, MIP-1α, MIP-1β as the major HIV-1-suppressive factors produced by CD8+ cells. Science (1995) 270:1811-1815.
   PubMed Web of Science ®Google Scholar
• BEN-BARUCH A, MICHIEL DF, OPPENHEIM J et al.: Signal and receptors involved in recruitment of inflammatory cells. J. Biol. Chem. (1995) 270(20):11703-11706.
   PubMed Web of Science ®Google Scholar
• TACHIBANA K, HIROTA S, IIZASA I et al.: The chemokine receptor CXCR4 is essential for vascularization of gastrointestinal tract. Nature (1998) 393:591-594.
   PubMed Web of Science ®Google Scholar
• ZOU Y, KOTTMANN A, KURODA M et al.: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature (1998) 393:595-596
   PubMed Web of Science ®Google Scholar
• CAO Y, QIN L, ZHANG L, SAFRIT J, HO DD: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. (1995) 332(4):201-208.
   PubMed Web of Science ®Google Scholar
• SHEARER GM, CLERICI M: Cytokine profiles in HIV type 1 disease and protection. AIDS Res. Hum. Retroviruses (1998) 14(Suppl. 2):S149-S152.
   PubMed Web of Science ®Google Scholar
• CLERICI M, BALOTTA C, SALVAGGIO A et al.: Human immunodeficiency virus (HIV) phenotype and interleukin-2/interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood (1996) 88(2):574-579.
   PubMed Web of Science ®Google Scholar
• HADIDA F, VIEILLARD V, AUTRAN B, CLARK-LEWIS I, BAGGIOLINI M, DEBRE P: HIV-specific T cell cytotoxicity mediated by RANTES via the chemokine receptor CCR3. J. Exp. Med. (1998) 188(3):609-614.
   PubMed Web of Science ®Google Scholar
• FENG Y, BRODER CC, KENNEDY PE, BERGER EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science (1996) 272:872-877.
   PubMed Web of Science ®Google Scholar
• DRAGIC T, LITWIN V, ALLAWAY GP et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR5. Nature (1996) 381:667-673.
   PubMed Web of Science ®Google Scholar
• DENG H, LIU R, ELLMEIER W et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 318:661-666.
   Google Scholar
• BLEUL CC, FARZAN M, CHOE H et al.: The lymphocytes chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature (1996) 382:829-833.
   PubMed Web of Science ®Google Scholar
• OBERLIN E, AMARA A, BACHELERIE F et al.: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (1996) 382:833-835.
   PubMed Web of Science ®Google Scholar
• CONNORS RI, SHERIDAN KE., CERADINI D, CHOE S, LANDAU NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. (1997) 185:621-628.
   PubMed Web of Science ®Google Scholar
• XIAO L, RUDOLPH DL, OWEN SM, SPIRA TJ, LAL RB: Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS (1998) 12(13):F137-F143.
   PubMed Web of Science ®Google Scholar
• VALENTIN A, ALBERT J, FENYO EM, ASJO B: Dual tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus type 1 and 2 isolates. J. Virol. (1994) 68(10):6684-6689.
   PubMed Web of Science ®Google Scholar
• SIMMONS G, WILKINSON D, REEVES JD et al.: Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J. Virol. (1996) 70(12):8355-8360.
   PubMed Web of Science ®Google Scholar
• MCKNIGHT A, WEISS R: Blocking the docking of HIV-1. Proc. Natl. Acad. Sci. USA (2003) 100(19):10581-10582.
   PubMed Web of Science ®Google Scholar
• KILBY JM, HOPKINS S, VENETTA TM et al.: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. (1998) 4:1302-1307.
   PubMed Web of Science ®Google Scholar
• LALEZARI J, HENRY K, O’HEARN M et al.: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. (2003) 348:2175-2185.
   PubMed Web of Science ®Google Scholar
• JACOBSON JM, LOWY I, FLETCHER CV et al.: Single-dose safety, pharmacology, and antiviral activity of human immunodeficiency virus (HIV) type 1 entry inhibitor PRO542 in HIV-infected adults. J. Infect. Dis. (2000) 182:326-329.
   PubMed Web of Science ®Google Scholar
• LIN P-F, BLAIR W, WANG T et al.: A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. USA (2003) 100:11013-11018.
   PubMed Web of Science ®Google Scholar
• FISCHER R, BERTONIS J, MEIER W et al.: HIV infection is blocked in vitro by recombinant soluble CD4. Nature (1988) 331:76-78.
   PubMed Web of Science ®Google Scholar
• DAAR ES, LI XL, MOUDGIL T, HO DD: High concentration of recombinant soluble CD4 are required to neutralize human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. USA (1990) 87:6574-6578.
   PubMed Web of Science ®Google Scholar
• SCHOOLEY RT, MERIGAN TC, GAUG P et al.: Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann. Intern. Med. (1990) 112:247-253.
   PubMed Web of Science ®Google Scholar
• RUSCONI S, SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: New advances in HIV entry inhibitors development. Curr. Drug Targets Infect. Disord. (2004) 4:339-355.
   PubMedGoogle Scholar
• NARDESE V, LONGHI R, POLO S et al.: Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES. Nat. Struct. Biol. (2001) 8(7):611-615.
   PubMedGoogle Scholar
• PROUDFOOT AEI, POWER CA, HOOGEWERF AJ et al.: Extension of recombinant human RANTES by retention of the initiating methionine produces a potent antagonist. J. Biol. Chem. (1996) 271:2599-2603.
   PubMed Web of Science ®Google Scholar
• SIMMONS G, CLAPHAM PR, PICARD L et al.: Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science (1997) 276:276-279.
   PubMed Web of Science ®Google Scholar
• MACK M, LUCKOW B, NELSON PJ et al.: Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. (1998) 187(8):1215-1224.
   PubMed Web of Science ®Google Scholar
• MOSIER DE, PICCHIO GR, GULIZIA RJ et al.: Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. (1999) 73(5):3544-3550.
   PubMed Web of Science ®Google Scholar
• SABBE R, PICCHIO GR, PASTORE C et al.: Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression. J. Virol. (2001) 75(2):661-671.
   PubMed Web of Science ®Google Scholar
• HARTLEY O, GARTNER H, WILKEN J et al.: Medicinal chemistry applied to synthetic protein: development of highly potent HIV entry inhibitors. Proc. Natl. Acad. Sci. USA (2004) 23:16460-16465.
   Google Scholar
• LEDERMAN M, VEAZEY R, OFFORD R et al.: Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science (2004) 306:485-487.
   PubMed Web of Science ®Google Scholar
• YANG OO, SWANBERG SL, LU Z et al.: Enhanced inhibition of human immunodeficiency virus type 1 by Met-stromal-derived-factor-1β correlates with down-regulation of CXCR4. J. Virol. (1999) 73:4582-4589.
   PubMed Web of Science ®Google Scholar
• RUSCONI S, MERRILL DP, LA SETA CATAMANCIO S et al.: In vitro inhibition of HIV-1 by Met-SDF-1β alone or in combination with antiretroviral drugs. Antiviral Ther. (2000) 5(3):199-204.
   PubMed Web of Science ®Google Scholar
• CHAN DC, KIM PS: HIV entry and its inhibition. Cell (1998) 93:681-684.
   PubMed Web of Science ®Google Scholar
• ECKERT DM, MALASHKEVICH VN, HONG LH, CARR PA, KIM PS: Inhibiting HIV-1 entry: discovery of d-peptide inhibitors that target the gp41 coiled-coil pocket. Cell (1999) 99(1):103-115.
   PubMed Web of Science ®Google Scholar
• FERRER M, KAPOOR TM, STRASSMAIER T et al.: Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat. Struct. Biol. (1999) 6(10):953-960.
   PubMedGoogle Scholar
• ROOT MJ, KAY MS, KIM S: Protein design of an HIV-1 entry inhibitor. Science (2001) 291(5505):884-888.
   PubMed Web of Science ®Google Scholar
• LAMBERT DM, ZHOU J, MEDINAS R et al.: HIV-1 isolates from patients treated with T-20 are sensitive to the second generation fusion inhibitor T1249. Antiviral Ther. (1999) 4(Suppl. 1):8.
   Google Scholar
• ARMAND-UGON M, CLOTET-CODINA I, TINTORI C et al.: The anti-HIV activity of ADS-J1 targets the HIV-1 gp120. Virology (2005) 343:141-149.
   PubMed Web of Science ®Google Scholar
• ALLAWAY G, DAVIS-BRUNO KL, BEAUDRY GA et al.: Expression and characterization of CD4–IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses (1995) 11(5):533-539.
   PubMed Web of Science ®Google Scholar
• SHEARER WT, ISRAEL RJ, STARR S et al.: Recombinant CD4–IgG2 in human immunedeficiency virus type 1-infected children: Phase I/2 study. J. Infect. Dis. (2000) 182:1774-1779.
   PubMed Web of Science ®Google Scholar
• JACOBSON JM, ISRAEL RJ, LOWY I et al.: Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob. Agents Chemother. (2004) 48(2):423-429.
   PubMed Web of Science ®Google Scholar
• MOORE JP, SATTENTAU QJ, KLASSE PJ, BURKLY LC: A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J. Virol. (1992) 66(8):4784-4793.
   PubMed Web of Science ®Google Scholar
• KURITZKES DR, JACOBSON J, POWDERLY WG et al.: Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis. (2004) 189(2):286-291.
   PubMed Web of Science ®Google Scholar
• STIEGLER G, KATINGER H: Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection. J. Antimicrob. Chemother. (2003) 51(4):757-759.
   PubMed Web of Science ®Google Scholar
• ARMBRUSTER C, STIEGLER GM, VCELAR BA et al.: A Phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS (2002) 16(2):227-233.
   PubMed Web of Science ®Google Scholar
• STIEGLER G, ARMBRUSTER C, VCELAR B et al.: Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a Phase I evaluation. AIDS (2002) 16(15):2019-2025
   PubMed Web of Science ®Google Scholar
• WANG T, ZHANG Z, WALLACE OB et al.: Discovery of 4-benzoyl-1- [(4-methoxy-1H- pyrrolo[2,3-b]pyridin- 3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4–gp120 interactions. J. Med. Chem. (2003) 46(20):4236-4239.
   PubMed Web of Science ®Google Scholar
• GUO Q, HO HT, DICKER I et al.: Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120–CD4 interactions. J. Virol. (2003) 77(19):10528-10536.
   PubMed Web of Science ®Google Scholar
• SI Z, MADANI N, COX J et al.: Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc. Natl. Assoc. Sci. (2004) 101:5036-5041.
   PubMed Web of Science ®Google Scholar
• HO H, FAN L, NOWICKA-SANS B et al.: Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J. Virol. (2006) 80:4017-4025.
   PubMed Web of Science ®Google Scholar
• VEAZEY RS, KLASSE PJ, SCHADER SM et al.: Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus cell fusion. Nature (2005) 438(7064):99-102.
   PubMed Web of Science ®Google Scholar
• HANNA G, LALEZARI J, HELLINGER J et al.: Antiviral activity, safety, and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV-1-infected subjects. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (2004):141 (Abstract).
   Google Scholar
• RUSCONI S, MOONIS M, MERRILL DP et al.: Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob. Agents Chemother. (1996) 40(1):234-236.
   PubMed Web of Science ®Google Scholar
• MAEDA K, NAKATA, H, MIYAKAWA et al.: AK602: a novel HIV-specific spirodiketopiperazine CCR5 inhibitor potent against a wide spectrum of R5-HIV. 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2003):10 (Abstract)
   Google Scholar
• LALEZARI J, THOMPSON M, KUMAR P et al.: Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS (2005) 19(14):1443-1448.
   PubMed Web of Science ®Google Scholar
• PECKHAM J, ANDERSON D, AQUINO C et al.: Design, synthesis and structure–activity relationship studies of novel 4,4-disubstituded piperidine based CCR5 antagonists as anti-HIV-1 agents. 230th American Chemical Society Meeting, Washington, DC, USA (2005).
   Google Scholar
• IMAMURA S, ISHIHARA Y, HATTORI T et al.: CCR5 antagonists as anti-HIV-1 agents. 1. Synthesis and biological evaluation of 5-oxopyrrolidine-3-carboxamide derivatives. Chem. Pharm. Bull. (Tokyo) (2004) 52(1):63-73.
   PubMed Web of Science ®Google Scholar
• IIZAWA Y, KANZAKI N, TAKASHIMA K et al.: Anti-HIV-1 activity of TAK-220, a small molecule CCR5 antagonist. 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2003):11 (Abstract).
   Google Scholar
• IMAMURA S, ICHIKAWA T, NISHIKAWA Y et al.: Discovery of the piperidine-4-carboxamide derivative TAK-220, a highly potent CCR5 antagonist anti-HIV-1 agent. 229th American Chemical Society Meeting, San Diego, USA (2005).
   Google Scholar
• BABA M, KANZAKI N, MIYAKE H et al.: TAK-652, a novel small molecule CCR5 antagonist with potent anti-HIV-1 activity. 12th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2005):541 (Abstrac).
   Google Scholar
• DORR P, MACARTNEY M, RICKETT G et al.: UK-427,857, a novel small molecule HIV entry inhibitor is a specific antagonist of the chemokine receptor CCR5. 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2003):12 (Abstract).
   Google Scholar
• POZNIAK A, FÄTKENHEUER G, JOHNSON M et al.: Effect of short-term monotherapy with UK-427,857 on viral load in HIV-infected patients. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA (2003):H-443 (Abstract).
   Google Scholar
• FATKENHEUER G, POZNIAK A, JOHNSON M et al.: Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. (2005) 11(11):1170-1172.
   PubMed Web of Science ®Google Scholar
• WESTBY M, LEWIS M, WHITCOMB J et al.: Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. (2006) 80 (10):4909-4920.
   PubMed Web of Science ®Google Scholar
• MUIRHEAD G, ABEL S, RUSSELL D et al.: An investigation of the effects of atazanavir and ritonavir boosted atazanavir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857. Seventh International Congress on Drug Therapy in HIV Infection, Glasgow, UK (2004):P283 (Abstract).
   Google Scholar
• KIM D, WAMG L, HALE JJ et al.: Potent 1,3,4-trisubstituded pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties. Bioorg. Med. Chem. Lett. (2005) 15(8):2129-2134.
   PubMed Web of Science ®Google Scholar
• VEAZEY RS, KLASSE PJ, KETAS TJ et al.: Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-immunodeficiency virus infection. J. Exp. Med. (2003) 198(10):1551-1562.
   PubMed Web of Science ®Google Scholar
• AMIS F, GAVRILOV S, KAJUMO F et al.: Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. (2003) 77(9):5201-5208.
   PubMed Web of Science ®Google Scholar
• TAGAT J, McCOMBIE S, NAZARENO D et al.: Discovery of potent, selective, and orally active CCR5 antagonists for the potential treatment of HIV infection. 225th American Chemical Society Meeting, New Orleans, USA (2003).
   Google Scholar
• OLSON WC, RABUT GEE, NAGASHIMA KA et al.: Differential inhibition of human immunodeficiency virus type 1 fusion, gp 120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J. Virol. (1999) 73(5):4145-4155.
   PubMed Web of Science ®Google Scholar
• TRKOLA A, KETAS TJ, NAGASHIMA KA et al.: Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO-140. J. Virol. (2001) 75(2):579-588.
   PubMed Web of Science ®Google Scholar
• NAGASHIMA KA, ROSENFIELD S, THOMPSON D et al.: Mechanisms of synergy between HIV-1 attachment, coreceptor and fusion inhibitors. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, USA (2001):310 (Abstract).
   Google Scholar
• ROSCHKE V, CLARK S, BRANCO L et al.: Characterization of a panel of novel human monoclonal antibodies that specifically antagonize CCR5 and block HIV entry. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, USA (2004):H-213 (Abstract).
   Google Scholar
• HOLMES MC, JOUVENOT Y, PEREZ E et al.: Towards gene knock out therapy for AIDS/HIV: targeted disruption of CCR5 using engineered zinc finger protein nucleases (ZFNs). 13th European Society of Gene Therapy, Prague, Czech Republic (2005).
   Google Scholar
• SCHOLS D, ESTE’ JA, HENSON G, DE CLERCQ E: Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res. (1997) 35(3):147-156.
   PubMed Web of Science ®Google Scholar
• DONZELLA GA, SCHOLS D, LIN SW et al.: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. (1998) 4:72-77.
   PubMed Web of Science ®Google Scholar
• FRICKER SP, ANASTASSOV V, COX J et al.: Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem. Pharmacol. (2006) 72(5):588-586
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: Potential clinical application of the CXCR4 antagonist bicyclam of AMD3100. Mini Rev. Med. Chem. (2005) 5(9):805-824
   PubMed Web of Science ®Google Scholar
• HATSE S, PRINCEN K, BRIDGER G et al.: Specific CXCR4 antagonist with potent anti-HIV activity. Antiviral Res. (2002) 53:3.
   Google Scholar
• MURAKAMI T, YOSHIDA A, KUMAKURA S et al.: KRH-2731-5HCL: a new potent and orally bioavailable X4 HIV-1 inhibiting CXCR4 antagonist in vivo. 15th International Conference on AIDS, Bangkok, Thailand (2004):LbOrA01 (Abstract).
   Google Scholar
• ROSENWIRTH B, DE BETHUNE MP, PTAK RG et al.: Debio-025, a novel non-immunosuppressive cyclosporine analog with potent anti-human immunodeficiency virus type 1 activity: pharmacological properties and mode of action. Antiviral Res. (2005) 65:3.
   Google Scholar
• VAILLANT A, JUTEAU JM, LU HONG et al.: Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. Antimicrob. Agents Chemother. (2006) 50(4):1393-1401.
   PubMed Web of Science ®Google Scholar
• DELMEDICO M, BRAY B, CAMMACK N et al.: Next generation HIV peptide fusion inhibitor candidates achieve potent, durable suppression of virus replication in vitro and improved pharmacokinetic properties. 13th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2006):48 (Abstract).
   Google Scholar
• CHOU T-C, TALALAY P: Quantitative analysis of dose effect relationships: the combined effect of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. (1984) 22:27-55.
   PubMedGoogle Scholar
• TREMBLAY CL, KOLLMAN C, GIGUEL F, CHOU T-C, HIRSCH MS: Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J. Acquir. Immune Defic. Syndr. (2000) 25(2):99-102.
   PubMed Web of Science ®Google Scholar
• TREMBLAY CL, GIGUEL F, KOLLMAN C et al.: Anti-human immunodeficiency interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob. Agents Chemother. (2002) 46(5):1336-1339.
   PubMed Web of Science ®Google Scholar
• RUSCONI S, LA SETA CATAMANCIO S, CITTERIO P et al.: Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections. J. Virol. (2000) 74(19):9328-9332.
   PubMed Web of Science ®Google Scholar
• NAGASHIMA KA, THOMPSON DAD, ROSENFIELD SI, MADDON, PJ, DRAGIC T, OLSON WC: Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus–cell and cell–cell fusion. J. Infect. Dis. (2001) 183:1121-1125.
   PubMed Web of Science ®Google Scholar
• PRINCEN K, HATSE S, VERMERE K et al.: Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist. J. Virol. (2004) 78(23):12993-13006.
   Google Scholar